Bicarbonate

Bicarbonate

SCHEMBL72939

O.O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3]

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CA4 P22748 5/20 0.46
CA1 P00915 2/20 0.46
FAHD1 Q6P587 1/20 0.46
LMNA P02545 2/20 0.36
MEN1 O00255 1/20 0.36
LDHA P00338 1/20 0.36
BLM P54132 1/20 0.36
KMT2A Q03164 1/20 0.36
CASP1 P29466 1/20 0.33
TP53 P04637 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL153476 1.00 CA4 (0.46) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL150638 1.00 CA4 (0.46) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL28576576 1.00 CA4 (0.46) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL1401747 1.00 CA4 (0.46) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL22476039 1.00 CA4 (0.46) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL150902 1.00 CA4 (0.46) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL3237788 0.94
Bicarbonate SCHEMBL14563499 0.94 CA4 (0.42) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL40504 0.94 CA4 (0.50) CA4CA1FAHD1LMNAMEN1
Bicarbonate SCHEMBL14563712 0.89 CA4 (0.39) CA4CA1FAHD1LMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119709198-A Eu3+/Mn4+Co-doped luminescent material, and preparation method and application thereof 安徽三联学院 2025-03-28 CN claimed
CN-119120018-A Mn (Mn)4+Doped deep red light luminescent material, and preparation method and application thereof 安徽三联学院 2024-12-13 CN claimed
US-12145131-B2 Polymeric lanthanum nanocomposite, and preparation method and application thereof NANJING UNIVERSITY (CN) 2024-11-19 US claimed
CN-117947461-A Preparation method, structure and application of non-noble metal oxide modified ultra-fine noble metal nano particles synthesized by low-temperature heat treatment 大连理工大学 2024-04-30 CN claimed
CN-112442367-B LED fluorescent powder capable of changing color along with temperature and preparation method and application thereof 南京邮电大学 2022-09-06 CN claimed
US-20220219142-A1 POLYMERIC LANTHANUM NANOCOMPOSITE, AND PREPARATION METHOD AND APPLICATION THEREOF NANJING UNIVERSITY (CN) 2022-07-14 US claimed
CN-114653356-A Preparation method of lanthanum-doped cerium dioxide catalyst material and formaldehyde-removing compound 江汉大学 2022-06-24 CN claimed
CN-114524452-A Nano lanthanum carbonate hydrate and preparation method and application thereof 浙江大学 2022-05-24 CN claimed
CN-110681368-B Resin-based nano lanthanum material, preparation method and application 南京大学 2021-10-26 CN claimed
CN-110664769-B Lanthanum carbonate orally disintegrating tablet and preparation method thereof 常州市阳光药业有限公司 2021-10-15 CN claimed
WO-2010131255-A1 PROCESS FOR THE PREPARATION OF LANTHANUM CARBONATE DIHYDRATE NATCO PHARMA LIMITED (IN) 2010-11-18 WO claimed
WO-2010085520-A1 DISINTEGRABLE FORMULATIONS OF LANTHANUM CARBONATE MYLAN INC. (US) 2010-07-29 WO claimed
US-20100015246-A1 COMBINATION OF A LANTHANUM COMPOUND AND BONE ENHANCING AGENT FOR THE TREATMENT OF BONE DISEASES SHIRE INTERNATIONAL LICENSING B.V. (NL) 2010-01-21 US claimed
EP-1294384-B1 USE OF LANTHANUM COMPOUNDS FOR THE TREATMENT OF BONE DISEASES SHIRE HOLDINGS AG (CH) 2009-03-11 EP claimed
WO-2007056721-A2 TREATMENT OF CHRONIC KIDNEY DISEASE (CKD) SUBJECTS USING LANTHANUM COMPOUNDS SHIRE INTERNATIONAL LICENSING B.V (NL) 2007-05-18 WO claimed
EP-1785142-A1 Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds Shire International Licensing B.V. (NL) 2007-05-16 EP claimed
US-20070104799-A1 Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds SHIRE INTERNATIONAL LICENSING B.V. (NL) 2007-05-10 US claimed
US-7192609-B2 Use of rare earth compounds for the prevention of kidney stone disease SHIRE INTERNATIONAL LICENSING B.V. (NL) 2007-03-20 US claimed
US-20070048390-A1 Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases SHIRE INTERNATIONAL LICENSING B.V. (NL) 2007-03-01 US claimed
US-7078059-B2 Treatment of bone diseases SHIRE HOLDINGS AG (CH) 2006-07-18 US claimed